| Code | CSB-MP013227HU1d9 |
| Abbreviation | Recombinant Human LTBR protein, partial (Active) |
| MSDS | |
| Size | $90 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
LTBR mediates lymphotoxin-β and LIGHT signaling to regulate lymphoid organogenesis, immune homeostasis, and inflammatory responses, making it a target of interest in autoimmune disease and cancer immunotherapy research. This mammalian-expressed construct spanning residues 31–227 captures the complete extracellular ligand-binding domain and demonstrates quantified binding to biotinylated human TNFSF14 (LIGHT) with an EC50 of 4.3–4.9 ng/mL in functional ELISA, providing a validated reagent for ligand-receptor interaction studies and competitive inhibition assays. The measured affinity supports use in screening blocking antibodies, epitope mapping of therapeutic candidates targeting the LTBR–LIGHT axis, and small-molecule inhibitor discovery campaigns where precise quantification of binding interference is required. Purity exceeding 95% by SDS-PAGE and endotoxin levels below 1.0 EU/μg align with standards expected in surface plasmon resonance, biolayer interferometry, and cell-based functional assays where contaminant interference must be minimized.
There are currently no reviews for this product.